About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

http://www.ptemag.com/pharmtecheurope/article/articleDetail.jsp?id=392072

THIS IS A GOOD READ

PER ERX RESULTS FORWARD LOOKING STATEMENT

We hope to continue to fund some of the desired development in the Company's
skill base through grant funding and partnering with Pharmaceutical majors. By
continuing to support the Company's development from compound discovery through
to the preclinical evaluation stage we believe that shareholder value will be
enhanced. The Company is open to exploring in-licensing and M&A options that
enable the acquisition of additional competences in medicinal chemistry and lead
optimisation, as and when the opportunity arises.

MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare Conference


MINNEAPOLIS--(BUSINESS WIRE)--Jan 3, 2007 - MGI Pharma, Inc. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI Pharma, will present at the JP Morgan 25th Annual Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2007 at 10:30 a.m. Pacific Standard Time. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.

The presentation will be webcast live and may be accessed by logging on to our corporate website at www.mgipharma.com. Please connect to the Company's website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through January 17, 2007.

Scientists find guardian gene's choices crucial to stopping cancer process
Save as PDF Print Email Blog It - +

Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have uncovered a novel pathway by which the anti-cancer gene p53 springs into action, protecting a damaged cell from becoming cancer. The gene can either halt the cell's growth or send it spiraling toward certain death. How this choice is made, the researchers say, could have implications for future strategies in chemotherapy drug development.


According to Steven McMahon, Ph.D., associate professor of cancer biology at Jefferson Medical College, who led the work, the p53 gene's or rather its protein's ability to direct a damaged cell to either stop growing or commit suicide depends on turning on separate groups of target genes. He and his co-workers have found that after a cell's DNA is damaged, the p53 protein's ability to bind to the DNA can be affected.

Two enzymes, hMOF and TIP60, can chemically alter an amino acid, lysine 120, at the binding site, in turn influencing p53's decision on which target genes to turn on. The alteration can short-circuit p53's ability to cause the damaged cell to commit suicide, though it can still stop cell growth, suggesting that this change may help explain a mechanism behind p53's choice. They report their findings in the journal Molecular Cell.

"It's been known that p53 can induce cell cycle arrest or apoptosis (programmed cell death) as a way of eliminating developing cancer cells in response to cell damage, but no one has known how the choice is made," says Dr. McMahon. "This work narrows how the decision is made."

The findings could have implications for future drug development strategies. "Most chemotherapy strategies are aimed at getting cancer cells to die," Dr. McMahon says. "Figuring out what pathways p53 uses to cause that versus cell cycle arrest is important. It looks like this new modification that we have identified helps p53 make that decision."



"p53 is such an important player in the cancerous process it's nearly always mutated or inactivated in cancer that continuing to understand more about how it works will likely have significant implications for cancer research," says Dr. McMahon. "We wouldlike to understand the interplay between this newly identified pathway and others involved in p53 and cancer.

"Since p53 can make this decision, this might give some insight into which function of p53 is more important in which tissues," says co-author Stephen Sykes, a Ph.D. candidate at the University of Pennsylvania. "For example, K120 (lysine 120) mutations cause tumors in the prostate, but are not so much involved in causing immune system cancers such as lymphomas. That could suggest that p53's potential to cause cell death could be more important in certain tissues than in others. In the future, if someone could develop therapies that could specifically activate p53's potential to drive programmed cell death versus the cell cycle arrest potential, it might influence how a doctor might choose to treat a certain type of cancer.

"This may potentially enable the development of a cancer drug that would stimulate the enzymes to promote this modification driving p53 to apoptosis."

Over 9 million sold out today, only 19,000 I know, price has dropped off considerably over last couple of weeks, the spread has narrowed, only question now is how far will it fall. I reckon 0.15p at least.

It's punters fed up with ph and his perpetual ramping that has done it.

I describe myself except I took a very small profit.

Bought a bottle of wine though.

sww nail on head :)

The sp is moving to match the 0.2p new placing Sareum management did a similar raising yesterday yet got a 40 % increase.
They raised 10% at increased price not a discount.
This level may well hold until some actual news which has been misssing for quite a few months.

OSI Pharma update 6pm tonight, dont miss the webcast

Bluehorshoe loves ERX

PH
I can see why

Thanks PH ,essential news on OSI Pharma ,they announced conversion period for there convertible senior notes.How exciting !!!!!

POTHEAD . DO YOU NOT REALISE PEOPLE ON THIS SITE LAUGH AT YOU, IF YOU ARE HOLDING A SUBSTANTIAL HOLDING ??? YOU ARE NOT DOING YOURSELF OR ANYONE ELSE ANY FAVOURS , I AM HOLDING 5M AND LIKE EVERYONE ELSE CAN ONLY WAIT FOR GOOD NEWS FOR OURSELVES AND ALL UNFORTUNATE CANCER SUFFERERS.

20 & 25 million sales just gone through.
Is anyone going to the AGM to ask what ERX are doing for so called shareholder value?

Dont worry Laurie, PH will be going to the AGM to represent the PIs

20&25m are not sales but buys!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

and i should add both the same punter who might he be!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
somebody who knows something you dont!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

eh pot'head..you said buy into this share but held off...is now a good time or should i wait for around 0.15p?

Bought into HML today up 103% SAR is also up 24.5% keep ERX on your radar it could be the next big riser.

hope so, rather disappointed with lack of news

BIOTECHNOLOGY

Drugmakers arms races could spur biotech deals


BLOOMBERG NEWS


Tuesday, January 16, 2007

Vincent Aita of Kilkenny Capital Management says he picks biotechnology stocks on their potential as takeover targets. The strategy is paying off.

The number of biotech deals, including acquisitions and product alliances, rose 32 percent to 232 last year, according to data compiled by Bloomberg.

Vincent Aita Broker who manages about $200 million in health stocks expects to see more biotech acquisitions.

At least four of Aita's holdings, including Serono SA and Kos Pharmaceuticals Inc., were bought by bigger drug makers. Aita, who manages about $200 million in health stocks, is expecting more transactions in 2007.

"There is an escalating arms race,'' Aita said in last week at the JP Morgan Healthcare Conference in San Francisco. "There are more deals to be had.''

Pfizer Inc., the world's largest pharmaceuticals maker, and Merck & Co. might buy biotech companies to make up for a scarcity of experimental medicines and expiring patents for best-selling products.

On the shopping list are companies with experimental compounds as well as those with new drug-development science and technologies, investors at the conference said.

Last year, the number of biotech deals in North America, including acquisitions and joint ventures, increased from 175 in 2005, and the average premium rose to 33 percent from 23 percent, based on Bloomberg data.

More transactions and higher premiums are likely this year, said analysts, investors and company executives at the conference, the annual meeting where buyers and sellers gather and make deals.

"Premiums are going up,'' JP Morgan analyst Geoffrey Meacham said. "You're seeing a lot of bidding wars.''

Driving the trend are big pharmaceutical companies with billions in cash that need to acquire new drugs to continue to ensure growth.

Pfizer could lose almost half of its sales as a result of generic drug competition with products that have expiring patents.

Pfizer has entered at least six research partnerships since November.

Merck, the fourth-largest U.S. drug maker, could lose $3 billion in sales this year from its top-selling Zocor cholesterol pill because of competition from generic versions.

It signed 35 transactions last year, including the $1.1 billion purchase of Sirna Therapeutics Inc., which is developing drugs based on blocking genes involved in disease.

Merck aims to become "the best biotechnology company,'' CEO Richard Clark said. Its biotech deals totaled $1.4 billion in 2006.

"It's science and technology and potential companies; we're looking at all ends of the spectrum,'' Clark said. "Obviously, it's competitive.''

Eli Lilly & Co., which is offering $2.28 billion to buy its biotech partner Icos Corp., is spending $1.5 billion this decade on building its own biotechnology operations.

"The price of poker has definitely gone up,'' said John Lechleiter, Lilly's president and chief operating officer. "There are too few good assets and too many bidders.''

Amgen Inc., the world's biggest biotechnology company, and Biogen Idec Inc. also are considering acquisitions and alliances.

Since May, Biogen has bought three companies with a combined value exceeding $270 million to reduce its reliance on its biggest product, the multiple sclerosis treatment Avonex.

The company agreed this month to pay as much as $120 million for Syntonix Pharmaceuticals Inc., adding experimental treatments for hemophilia.

The pace of acquisitions "is the most active in our history,'' Biogen CEO James Mullen told investors at the conference.

Premiums over the market price of traded shares also are rising.

They ranged from 21 percent for Swiss drug maker Actelion Ltd.'s purchase of Cotherix Inc., a U.S. biotech company, to 170 percent for AnorMed Inc., which Genzyme Corp. took over in a bidding war with rival Millennium Pharmaceuticals Inc.

Genzyme's takeover of AnorMed was last year's first hostile bid by a biotechnology company, said Steven Burrill, CEO of Burrill & Co., a life-sciences investment adviser in San Francisco.

"Premiums are running 50 percent to 100 percent, which means the market is undervaluing the stocks," he said.